Jack A. Khattar Supernus Pharmaceuticals, Inc. (SUPN) insider trading activity

SUPN Quotes by TradingView

Jack A. Khattar is President, CEO of SUPERNUS PHARMACEUTICALS, INC.. Currently has a direct ownership of 1.07 Million shares of SUPN, which is worth approximately $44.1 Million. The most recent transaction as insider was on Nov 21, 2022, when has been sold 848 shares (Common Stock) at a price of $9.56 per share, resulting in proceeds of $8,106. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 1.07M
6.07% 3M change
16.9% 12M change
Total Value Held $44.1 Million

Jack A. Khattar Transaction History

Date Transaction Value Shares Traded Shares Held Form
Nov 21 2022
BUY
Exercise of conversion of derivative security
$8,106 $9.56 p/Share
848 Added 0.11%
781,590 Common Stock
Nov 15 2022
SELL
Open market or private sale
$39,025 $35.0 p/Share
1,115 Reduced 0.14%
780,742 Common Stock
Nov 15 2022
BUY
Exercise of conversion of derivative security
$17,045 $9.56 p/Share
1,783 Added 0.23%
781,857 Common Stock
Sep 14 2022
SELL
Exercise of conversion of derivative security
$46,575 $33.75 p/Share
1,380 Reduced 0.18%
780,074 Common Stock
Sep 14 2022
BUY
Exercise of conversion of derivative security
-
5,895 Added 0.75%
781,454 Common Stock
Aug 16 2022
SELL
Exercise of conversion of derivative security
$312,280 $34.01 p/Share
9,182 Reduced 1.15%
790,249 Common Stock
Aug 16 2022
SELL
Open market or private sale
$499,607 $34.01 p/Share
14,690 Reduced 1.86%
775,559 Common Stock
Aug 16 2022
BUY
Exercise of conversion of derivative security
-
39,530 Added 4.71%
799,431 Common Stock
Aug 15 2022
SELL
Exercise of conversion of derivative security
$367,966 $34.03 p/Share
10,813 Reduced 1.37%
777,203 Common Stock
Aug 15 2022
SELL
Open market or private sale
$588,787 $34.03 p/Share
17,302 Reduced 2.23%
759,901 Common Stock
Aug 15 2022
BUY
Exercise of conversion of derivative security
-
46,575 Added 5.58%
788,016 Common Stock
Aug 10 2022
SELL
Open market or private sale
$887,803 $31.22 p/Share
28,437 Reduced 3.69%
741,441 Common Stock
Aug 10 2022
BUY
Exercise of conversion of derivative security
-
44,900 Added 5.51%
769,878 Common Stock
Aug 09 2022
SELL
Open market or private sale
$1,228,276 $31.15 p/Share
39,431 Reduced 5.16%
724,978 Common Stock
Aug 09 2022
BUY
Exercise of conversion of derivative security
-
63,100 Added 7.63%
764,409 Common Stock
Aug 08 2022
SELL
Open market or private sale
$3,744,726 $31.76 p/Share
117,907 Reduced 14.39%
701,309 Common Stock
Aug 08 2022
BUY
Exercise of conversion of derivative security
-
192,000 Added 18.99%
819,216 Common Stock
Mar 18 2022
BUY
Other acquisition or disposition
-
10,750 Added 1.69%
627,216 Common Stock
Mar 14 2022
BUY
Grant, award, or other acquisition
-
60,000 Added 8.87%
616,466 Common Stock
Jul 30 2021
BUY
Grant, award, or other acquisition
-
40,000 Added 6.71%
556,466 Common Stock
Mar 26 2021
BUY
Other acquisition or disposition
-
10,000 Added 1.9%
516,466 Common Stock

Also insider at

SCPH
scPharmaceuticals Inc. Healthcare
CGTX
COGNITION THERAPEUTICS INC Healthcare
Director
JAK

Jack A. Khattar

President, CEO
Rockville, MD

Track Institutional and Insider Activities on SUPN

Follow SUPERNUS PHARMACEUTICALS, INC. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells SUPN shares.

Notify only if

Insider Trading

Get notified when an Supernus Pharmaceuticals, Inc. insider buys or sells SUPN shares.

Notify only if

News

Receive news related to SUPERNUS PHARMACEUTICALS, INC.

Choose your preferred platform and Sign Up 👇 Telegram Email
Track Activities on SUPN